None of these agents resulted in a decrease in the mortality rate, liver failure, or perioperative morbidity in clinical setting, even though some promising pharmaceuticals engendered an improvement in the secondary outcomes of AST, ALT, and some other molecules. This evidence concerns the gene GPT and liver failure.